Free Trial
NASDAQ:TFFP

TFF Pharmaceuticals Q1 2024 Earnings Report

TFF Pharmaceuticals EPS Results

Actual EPS
-$2.40
Consensus EPS
-$2.20
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

TFF Pharmaceuticals Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
$0.15 million
Beat/Miss
Beat by +$50.00 thousand
YoY Revenue Growth
N/A

TFF Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
4:00PM ET

TFF Pharmaceuticals Earnings Headlines

TFF Pharmaceuticals approves dissolution plan
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
TFF Pharmaceuticals Shares Fall 66%; Company to Wind Down
TFF Pharmaceuticals terminates employees, to wind down operations
See More TFF Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TFF Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TFF Pharmaceuticals and other key companies, straight to your email.

About TFF Pharmaceuticals

TFF Pharmaceuticals (NASDAQ:TFFP), a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

View TFF Pharmaceuticals Profile

More Earnings Resources from MarketBeat